文献速递肿瘤 PET/CT

双受体靶向示踪剂[68Ga]Ga-HX01在10种不同皮下及原位肿瘤模型中的临床前评价

Preclinical evaluation of a dual-receptor targeted tracer [68Ga]Ga-HX01 in 10 different subcutaneous and orthotopic tumor models.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-08-29

本研究在10种人肿瘤皮下及原位小鼠模型中临床前评价了靶向整合素αvβ3与氨肽酶N(APN/CD13)的双受体探针[68Ga]Ga-HX01。BxPC-3模型中双靶点探针表现优于单靶点探针,各阻断组及单靶点组肿瘤摄取显著下降;[68Ga]Ga-HX01的肿瘤/肌肉与肿瘤/血比值高于[18F]FDG。作者认为该双靶点显像剂在不同小鼠模型中体内表现优于[18F]FDG及相应单受体靶向探针,值得未来临床转化用于肿瘤显像。

要点

  • 在BxPC-3模型中[68Ga]Ga-HX01显著优于单靶点探针,阻断组及单靶点组肿瘤摄取均显著下降。
  • BxPC-3、MCF-7、NOZ皮下瘤摄取高(%ID/g>1.1),HCC827、SK-OV-3、HCT-8、HuH-7为中等摄取(%ID/g 0.7-1.0)。
  • [68Ga]Ga-HX01的肿瘤/肌肉与肿瘤/血比值高于[18F]FDG。

核心结论

  • [68Ga]Ga-HX01作为双靶点显像剂,在多种人肿瘤皮下及原位小鼠模型中体内表现优于[18F]FDG及相应单受体靶向探针,值得未来临床转化用于肿瘤显像。

研究设计与样本

  • 研究为临床前评价,在10种不同皮下及原位肿瘤模型中进行。
  • 模型包括胰腺(BxPC-3)、乳腺(MCF-7)、胆囊(NOZ)、肺(HCC827)、卵巢(SK-OV-3)、结直肠(HCT-8)、肝(HuH-7)、胃(NUGC-4)和胶质瘤(U87)肿瘤。
  • 在BxPC-3异种移植模型中通过系列阻断研究和部分突变示踪剂确认双受体靶向能力。
  • 在BxPC-3异种移植模型中进行动态显像研究和剂量递增研究以确定最佳显像时间点和剂量。
  • 所有模型在接种后约2周行[68Ga]Ga-HX01 PET/CT显像,其中一部分同期行[18F]FDG PET/CT扫描并比较结果;另进行离体生物分布研究验证无创PET图像的半定量结果。

主要发现

  • [68Ga]Ga-HX01在BxPC-3异种移植模型中显著优于单靶点探针。
  • 所有阻断组和单靶点组均显示肿瘤摄取显著下降。
  • BxPC-3、MCF-7和NOZ皮下瘤中观察到高肿瘤摄取(%ID/g>1.1)。
  • HCC827、SK-OV-3、HCT-8和HuH-7皮下瘤中观察到中等摄取(%ID/g 0.7-1.0)。
  • 由于背景低,[68Ga]Ga-HX01的肿瘤/肌肉和肿瘤/血比值高于[18F]FDG。

关键数值与推荐

  • 高肿瘤摄取定义为%ID/g>1.1,见于BxPC-3、MCF-7和NOZ皮下瘤。
  • 中等摄取定义为%ID/g 0.7-1.0,见于HCC827、SK-OV-3、HCT-8和HuH-7皮下瘤。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The integrin αvβ3 and aminopeptidase N (APN/CD13) play vital roles in the tumor angiogenesis process. They are highly expressed in a variety of tumor cells and proliferating endothelial cells during angiogenesis, which have been considered as highly promising targets for tumor imaging. Arginine-glycine-aspartic (RGD) and asparagine-glycine-arginine (NGR) are two peptides specifically binding to the integrin αvβ3 and CD13, respectively. In this study, we optimized our previously developed probe and preclinically evaluated the new integrin αvβ3 and CD13 dual-targeted probe, NOTA-RGD-NGR (denoted as HX01) radiolabeled with 68Ga, in 10 different subcutaneous and orthotopic tumor models. METHODS: The specific activity and radiochemical purity of [68Ga]Ga-HX01 were identified. The dual-receptor targeting ability was confirmed by a series of blocking studies and partly muted tracers using BxPC-3 xenograft model. The dynamic imaging study and dose escalation study were explored to determine the optimal imaging time point and dosage in the BxPC-3 xenograft model. Next, we established a variety of subcutaneous and orthotopic tumor models including pancreas (BxPC-3), breast (MCF-7), gallbladder (NOZ), lung (HCC827), ovary (SK-OV-3), colorectal (HCT-8), liver (HuH-7), stomach (NUGC-4), and glioma (U87) cancers. All models underwent [68Ga]Ga-HX01 PET/CT imaging about 2 weeks post-inoculation, with a subset of them undergoing [18F]FDG PET/CT scan performed concurrently, and their results were compared. In addition, ex vivo biodistribution studies were also performed for verifying the semi-quantitative results of the non-invasive PET images. RESULTS: [68Ga]Ga-HX01 significantly outperformed single target probes in the BxPC-3 xenograft model. All blocking and single target groups exhibited significantly descending tumor uptake. The high tumor uptakes were found in BxPC-3, MCF-7, and NOZ subcutaneous tumors (%ID/g > 1.1), while middle uptakes were observed in HCC827, SK-OV-3, HCT-8, and HuH-7 subcutaneous tumor (%ID/g 0.7-1.0). Due to the low background, the tumor-to-muscle and tumor-to-blood ratios of [68Ga]Ga-HX01 were higher than that of [18F]FDG. CONCLUSIONS: [68Ga]Ga-HX01, as a dual target imaging agent, exhibited superior in vivo performance in different subcutaneous and orthotopic mice models of human tumors over [18F]FDG and its respectively mono-receptor targeted agents, which warrants the future clinical translation for tumor imaging.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Lv X, Song X, Long Y, et al. Preclinical evaluation of a dual-receptor targeted tracer [68Ga]Ga-HX01 in 10 different subcutaneous and orthotopic tumor models. Eur J Nucl Med Mol Imaging. 2023. PMID: 37642706. doi:10.1007/s00259-023-06412-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。